Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




FIND Receives Grant for Diagnostics from Dutch Government

By Labmedica staff writers
Posted on 29 Nov 2006
The Dutch Government has approved the Foundation for Innovative New Diagnostics' (FIND, Geneva, Switzerland) application for a grant to develop improved diagnostics for tuberculosis (TB), the human immunodeficiency virus (HIV), and malaria. More...


The grant amounts to U.S.$10.1 million over a period of four years, beginning November 2006. The grant is to finance gaps in existing plans and programs to develop simple, accurate, and rapid molecular tests for TB, HIV, and malaria.

The point-of-care products to be developed by FIND will include chemical sensor arrays for the detection of volatile compounds in the sputum of TB infected individuals, an improved lateral-flow assay to diagnose malaria in a finger-prick blood sample, and a lateral-flow assay to diagnose TB by detecting Mycobacterium tuberculosis (MTb) antigens in urine.

FIND also plans to develop a simple nucleic acid amplification test for the detection of TB in urine, a simple amplification test for the detection of malaria from whole blood, and a hands-free automated nucleic acid amplification test (NAAT) for HIV viral load in blood at first-referral laboratory level.

In the first quarter of 2007 FIND plans to launch a project on laboratory preparedness for the introduction of new technologies in Uganda, with the aim to strengthen laboratory diagnostic services in that country.




Related Links:
FIND

New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Repetitive Pipette
VWR® Stepper Pro
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.